– DENMARK, Copenhagen – Serendex Pharmaceuticals A/S, during its Annual General Meeting which took place today, April 30 2015 in Copenhagen, elected Don deBethizy as a new member of the Board of Directors, and confirmed working to raise new capital in the range of DKK 100-150 million going forward.
About Serendex Pharmaceuticals A/S
Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis), BE (bronchiectasis), CF (cystic fibrosis related lung infections) and DAH (diffuse alveolar hemorrhage). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company’s sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Repositioning reduces the time to market and the costs of development.
Serendex Pharmaceuticals is listed at Oslo Axess.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.